Fig. 5.

The therapeutic efficacy of LLS2 against MPNST cells. (A) Cell survival of NF96.2 and NF2.2 MPNST cells treated with indicated concentrations of LLS2 for 72 h. Half-maximal inhibitory concentrations of LLS2 on NF96.2 and NF2.2 are 21.3 μM and 31.2 μM, respectively. (B) Caspase-3/7 activities in NF96.2 and NF2.2 cells after 24 h treated with 0.25% DMSO or 25 µM LLS2 (C) Representative images and quantification of colony formation. (D) Active Ras pull-down assay. MPNST cells were treated with 0.25% DMSO or 25 μM LLS2, and cell lysates were prepared at 24 h, followed by incubating with Raf-1 RBD agarose. Input: total protein extracted from MPNST cells were not incubated with Raf-1 RBD agarose. Eluted proteins were analyzed by SDS-PAGE and immunoblotted with RAS antibodies. (E) Immunoblots of CXCR4, phospho-MEK, MEK, phospho-ERK, and ERK in NF96.2 and NF2.2 treated with vehicle control 0.25 % DMSO or 25 μM LLS2 for 24 h. ***P < 0.001; 2-tailed Student’s t-test. Data shown are mean ± SD.